Market closedNon-fractional
Aerovate Therapeutics/AVTE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Aerovate Therapeutics
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.
Ticker
AVTE
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Waltham, United States
Employees
51
Website
aerovatetx.com
AVTE Metrics
BasicAdvanced
$49M
Market cap
-
P/E ratio
-$3.03
EPS
1.39
Beta
-
Dividend rate
Price and volume
Market cap
$49M
Beta
1.39
Financial strength
Current ratio
6.653
Quick ratio
6.401
Long term debt to equity
0.362
Total debt to equity
0.851
Management effectiveness
Return on assets (TTM)
-47.78%
Return on equity (TTM)
-80.58%
Valuation
Price to book
0.52
Price to tangible book (TTM)
0.52
Price to free cash flow (TTM)
-0.662
Growth
Earnings per share change (TTM)
30.48%
3-year earnings per share growth
-59.55%
What the Analysts think about AVTE
Analyst Ratings
Majority rating from 7 analysts.
AVTE Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$23M
13.24%
Profit margin
0.00%
NaN%
AVTE Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.76
-$0.71
-$0.74
-$0.83
-
Expected
-$0.70
-$0.69
-$0.71
-$0.77
-$0.80
Surprise
9.20%
2.66%
4.57%
8.50%
-
AVTE News
AllArticlesVideos
Investigation Into Aerovate Therapeutics, Inc. (AVTE) Announced byHolzer & Holzer, LLC
GlobeNewsWire·2 weeks ago
Aerovate Therapeutics Investors: Investigation on behalf of investors; the Portnoy Law Firm
GlobeNewsWire·2 weeks ago
SHAREHOLDER ALERT: Aerovate Therapeutics Investigated for Securities Fraud Violations by Block & Leviton
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Aerovate Therapeutics stock?
Aerovate Therapeutics (AVTE) has a market cap of $49M as of July 06, 2024.
What is the P/E ratio for Aerovate Therapeutics stock?
The price to earnings (P/E) ratio for Aerovate Therapeutics (AVTE) stock is 0 as of July 06, 2024.
Does Aerovate Therapeutics stock pay dividends?
No, Aerovate Therapeutics (AVTE) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Aerovate Therapeutics dividend payment date?
Aerovate Therapeutics (AVTE) stock does not pay dividends to its shareholders.
What is the beta indicator for Aerovate Therapeutics?
Aerovate Therapeutics (AVTE) has a beta rating of 1.39. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Aerovate Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.